Biologic-device delivery device switch

A biotech manufacturer sought to switch a vialed lyophilized injectable biologic to a liquid pre-filled cartridge and pen. There was no significant change in drug-contacting materials. Chimera assisted in planning comparability, compatibility and stability protocols and drafted CMC documentation for the sBLA.